WFU researchers develop new platinum-based anti-tumor compound

February 11, 2009

Researchers in the Department of Chemistry at Wake Forest University in collaboration with colleagues at the Wake Forest University Health Sciences Comprehensive Cancer Center have developed a new class of platinum-based anti-tumor drugs that animal studies have shown to be 10 times more effective than current treatments in destroying certain types of lung cancer cells.

The results were published in the December 11 issue of the Journal of Medicinal Chemistry and highlighted in Science-Business eXchange (SciBX), produced by the publisher of the journal Nature. They suggest a new approach to fighting non-small cell lung cancer, which accounts for more than three-quarters of all lung cancers. Lung cancer is the leading cause of cancer-related deaths in both men and women. Less than a third of non-small cell lung cancer patients respond to traditional platinum-based therapies, and those who do respond have a median survival of less than a year.

"We are able to slow the growth of this cancer substantially in mice," said principal investigator Ulrich Bierbach, Z. Smith Reynolds Foundation Fellow and associate professor of chemistry at Wake Forest. "That is very good news, since this is such a rapidly growing, intractable type of cancer."

The new compound's potency derives from its ability to rapidly bind with and disable a tumor cell's DNA before the cell's natural repair mechanisms are activated. That repair process causes drug resistance, which reduces the effectiveness of currently used platinum-based drugs.

Bierbach has focused his research efforts since 1992 on finding ways to overcome the resistance problems inherent in platinum-based drugs. He joined the Wake Forest faculty in 1999, and since 2001, has led a research team that included participation by eight graduate students and more than 30 undergraduate students. The recent paper marks the 25th he has published on the topic.

"If this ends up in clinical trials in the next few years, that will fulfill a dream of mine," Bierbach said.

His research efforts will now be directed toward finding ways to boost the tumor-killing potency of the new compounds while reducing harmful side effects.
-end-
The new hybrid compounds are available for licensing from the Wake Forest University Office of Technology Asset Management.

Wake Forest University

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.